Philip Thompson, MBBS, is an Assistant Professor in the Department of Leukemia, Division of Cancer Medicine at the University of Texas MD Anderson Cancer Center, Houston, TX. Dr Thompson obtained his MBBS degree in hematology from the University of Melbourne, Parkville, Australia.
Dr Thompson has received various honors and awards, namely the MD Anderson Leukemia Department Clinical Fellow of the Year award in 2014 and the Shannon Timmins Fellowship in Leukemia Research.
Speaking on chronic lymphocytic leukemia and novel treatments
Dr Thompson’s work has included various clinical trials investigating the use of novel agents in chronic lymphocytic leukemia (CLL). One such trial he has been involved in is a Phase II trial assessing the efficacy of ibrutinib in the presence or absence of rituximab in relapsed CLL patients. Dr Thompson has also been extensively involved in the research behind predictive genomic markers for treatment response in CLL.